Epcoritamab-CAR T Cells for Large B-cell Lymphomas

Epcoritamab-CAR T Cells for Large B-cell Lymphomas
Conditions: Lymphoma, Non-Hodgkin; Relapsed Diffuse Large B Cell Lymphoma; Refractory Diffuse Large B-cell Lymphoma; High-grade B-cell Lymphoma; Transformed Indolent Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma

Interventions: Drug: Epcoritamab

Sponsors: Abramson Cancer Center at Penn Medicine; Genmab

Not yet **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

June 17, 2024Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine
Comments